Gemtuzumab ozogamicin in non-acute promyelocytic acute myeloid leukemia

Bibliography

• Juliusson G, Antunovic P, Derolf A, Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179-87
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115(3):453-74
   PubMed Web of Science ®Google Scholar
• Arber DA, Vardiman JW, Brunning RD, Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. WHO Press; Geneva, Switzerland: 2008
   Google Scholar
• Schlenk RF, Ganser A, Dohner K. Prognostic and predictive effect of molecular and cytogenetic aberrations in acute myeloid leukemia. ASCO Educational Book. 2010. p. 228-32
   Google Scholar
• Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006;368:1894-907
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S, Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006;108:3280-8
   PubMed Web of Science ®Google Scholar
• Kayser S, Dohner K, Krauter J, The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood 2011;117:2137-45
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 1989;7:1268-74
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114-24
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Ossenkoppele GJ, van Putten W, High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009;361:1235-48
   PubMed Web of Science ®Google Scholar
• Freeman SD, Kelm S, Barber EK, Crocker PR. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995;85:2005-12
   PubMed Web of Science ®Google Scholar
• Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 2007;7:255-66
   PubMed Web of Science ®Google Scholar
• Andrews RG, Torok-Storb B, Bernstein ID. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983;62:124-32
   PubMed Web of Science ®Google Scholar
• Simmons D, Seed B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J Immunol 1988;141:2797-800
   PubMed Web of Science ®Google Scholar
• Gao Z, McAlister VC, Williams GM. Repopulation of liver endothelium by bone-marrow-derived cells. Lancet 2001;357:932-3
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Soiffer RJ, Freedman AS, Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood 1992;79:2229-36
   PubMed Web of Science ®Google Scholar
• Griffin JD, Linch D, Sabbath K, A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 1984;8:521-34
   PubMed Web of Science ®Google Scholar
• Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005;19:176-82
   PubMed Web of Science ®Google Scholar
• Jilani I, Estey E, Huh Y, Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol 2002;118:560-6
   PubMed Web of Science ®Google Scholar
• Hamann PR, Hinman LM, Hollander I, Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem 2002;13:47-58
   PubMed Web of Science ®Google Scholar
• Zein N, Sinha AM, McGahren WJ, Ellestad GA. Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science 1988;240(4856):1198-201
   PubMed Web of Science ®Google Scholar
• van Der Velden VH, te Marvelde JG, Hoogeveen Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001;97:3197-204
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kano Y, Akutsu M, The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Res 2009;29:4589-96
   Google Scholar
• Walter RB, Raden BW, Kamikura DM, Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005;105:1295-302
   PubMed Web of Science ®Google Scholar
• Linenberger ML, Hong T, Flowers D, Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood 2001;98:988-94
   PubMed Web of Science ®Google Scholar
• Walter RB, Gooley TA, van der Velden VH, CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood 2007;109:4168-70
   PubMed Web of Science ®Google Scholar
• Rutella S, Bonanno G, Procoli A, Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. Exp Hematol 2006;34:54-65
   PubMed Web of Science ®Google Scholar
• ten Cate B, Samplonius DF, Bijma T, The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia 2007;21:248-52
   PubMed Web of Science ®Google Scholar
• van der Velden VH, Boeckx N, Jedema I, High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004;18:983-8
   PubMed Web of Science ®Google Scholar
• Dowell JA, Korth-Bradley J, Liu H, Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 2001;41:1206-14
   PubMed Web of Science ®Google Scholar
• Korth-Bradley JM, Dowell JA, Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy 2001;21:1175-80
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitz J, Chen G, Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490-6
   PubMed Web of Science ®Google Scholar
• Sievers EL, Appelbaum FR, Spielberger RT, Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a Phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood 1999;93:3678-84
   PubMed Web of Science ®Google Scholar
• Stone RM, Moser B, Sanford B, High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902. Leuk Res 2011;35:329-33
   PubMed Web of Science ®Google Scholar
• Sievers EL, Larson RA, Stadtmauer EA, Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001;19:3244-54
   PubMed Web of Science ®Google Scholar
• Larson RA, Boogaerts M, Estey E, Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia 2002;16:1627-36
   PubMed Web of Science ®Google Scholar
• Larson RA, Sievers EL, Stadtmauer EA, Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005;104:1442-52
   PubMed Web of Science ®Google Scholar
• Taksin AL, Legrand O, Raffoux E, High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia 2007;21:66-71
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Knovich MA, Bayer RL, Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia. Leuk Lymphoma 2002;43:1951-5
   PubMed Web of Science ®Google Scholar
• van der Heiden PL, Jedema I, Willemze R, Barge RM. Efficacy and toxicity of gemtuzumab ozogamicin in patients with acute myeloid leukemia. Eur J Haematol 2006;76:409-13
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Martinelli G, Rondoni M, Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. Leuk Lymphoma 2004;45:1791-5
   PubMed Web of Science ®Google Scholar
• Wadleigh M, Richardson PG, Zahrieh D, Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578-82
   PubMed Web of Science ®Google Scholar
• McKoy JM, Angelotta C, Bennett CL, Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007;31:599-604
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K, Krauter J. All-Trans retinoic acid and gemtuzumab ozogamicin as adjunct to high-dose cytarabine-based salvage therapy in primary refractory acute myeloid leukemia: results of AMLSG 05-04 trial. Annual Meeting of the American Society of Hematology 2007. Available at: All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct to High-Dose Cytarabine-Based Salvage Therapy in Primary Refractory Acute Myeloid Leukemia
   Google Scholar
• Burnett AK, Hills RK, Milligan D, Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol 2011;29:369-77
   PubMed Web of Science ®Google Scholar
• McDonald GB. Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma 2002;2(Suppl 1):S35-9
   PubMedGoogle Scholar
• Apostolidou E, Cortes J, Tsimberidou A, Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia. Leuk Res 2003;27:887-91
   PubMed Web of Science ®Google Scholar
• Cortes J, Tsimberidou AM, Alvarez R, Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia. Cancer Chemother Pharmacol 2002;50:497-500
   PubMed Web of Science ®Google Scholar
• Tsimberidou A, Cortes J, Thomas D, Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res 2003;27:893-7
   PubMed Web of Science ®Google Scholar
• Alvarado Y, Tsimberidou A. Kantarjian Het al. Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia. Cancer Chemother Pharmacol 2003;51:87-90
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Martinelli G, Rondoni M, First experience with gemtuzumab ozogamicin plus cytarabine as continuous infusion for elderly acute myeloid leukaemia patients. Leuk Res 2004;28:987-90
   PubMed Web of Science ®Google Scholar
• Specchia G, Pastore D, Carluccio P, Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience. Ann Hematol 2007;86:425-8
   PubMed Web of Science ®Google Scholar
• Martin MG, Augustin KM, Uy GL, Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol 2009;84:733-7
   PubMed Web of Science ®Google Scholar
• Chevallier P, Delaunay J, Turlure P, Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. J Clin Oncol 2008;26:5192-7
   PubMed Web of Science ®Google Scholar
• Litzow MR, Othus M, Cripe LD, Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 2010;148:217-25
   PubMed Web of Science ®Google Scholar
• Prebet T, Etienne A, Devillier R, Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: results of a retrospective comparative study. Cancer 2011;117:974-81
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Maciejewski JP, Erba HP, A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia. Cancer 2011;117:1253-61
   PubMed Web of Science ®Google Scholar
• Chevallier P, Prebet T, Pigneux A, Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin. Leukemia 2010;24:467-9
   PubMed Web of Science ®Google Scholar
• Schlenk RF, Dohner K. Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 2009;16:98-104
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Beck J, Graux C, Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood 2010;115:2586-91
   PubMed Web of Science ®Google Scholar
• Fernandez HF, Sun Z, Litzow MR, Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood 2011;117:5306-13
   PubMed Web of Science ®Google Scholar
• Kell WJ, Burnett AK, Chopra R, A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood 2003;102:4277-83
   PubMed Web of Science ®Google Scholar
• Amadori S, Suciu S, Willemze R, Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica 2004;89:950-6
   PubMed Web of Science ®Google Scholar
• Tsimberidou A, Estey E, Cortes J, Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer 2003;97:1481-7
   PubMed Web of Science ®Google Scholar
• Estey EH, Thall PF, Giles FJ, Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002;99:4343-9
   PubMed Web of Science ®Google Scholar
• Clavio M, Vignolo L, Albarello A, Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol 2007;138:186-95
   PubMed Web of Science ®Google Scholar
• McHayleh W, Foon K, Redner R, Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia. Cancer 2010;116:3001-5
   PubMed Web of Science ®Google Scholar
• Petersdorf S, Kopecky K, Stuart RK. Preliminary Results of Southwest Oncology Group Study S0106: An International Intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract 790]. Annual Meeting of the American Society of Hematology. New Orleans 2009, Available from: http://ash.confex.com/ash/2009/webprogram/Paper22999.html
   Google Scholar
• Fernandez HF, Sun Z, Yao X, Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009;361:1249-59
   PubMed Web of Science ®Google Scholar
• Acute Leukemia French Association. A randomized study of gemtuzumab ozogamicin (GO) with daunorubicine and cytarabine in untreated acute myeloid leukemia (AML) aged of 50 – 70 years old. ClinicalTrials.gov: NCT00927498 Available from: http://clinicaltrials.gov/ct2/show/NCT00927498
   Google Scholar
• Ravandi F. Gemtuzumab Ozogamicin: one size does not fit all—the case for personalized therapy. J Clin Oncol 2011;29:349-51
   PubMed Web of Science ®Google Scholar
• University of Ulm. Study of chemotherapy in combination with all-trans retinoic acid (ATRA) with or without gemtuzumab ozogamicin in patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation. ClinicalTrials.gov: NCT00893399 Available from: http://clinicaltrials.gov/ct2/show/NCT00893399
   Google Scholar